KURA ONCOLOGY, INC.

(KURA)
  Report
Real-time Estimate Cboe BZX  -  05/25 01:09:45 pm EDT
11.84 USD   -2.35%
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KURA ONCOLOGY, INC. : Other Events (form 8-K)

01/20/2022 | 04:27pm EDT

Item 8.01 Other Events.

On January 20, 2022, Kura Oncology, Inc. (the "Company") reported that the U.S. Food and Drug Administration (the "FDA") has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia ("AML"). The partial clinical hold was lifted following agreement with the FDA on the Company's mitigation strategy for differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about KURA ONCOLOGY, INC.
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Kura Oncology Reports First Quarter 2022 Financial Results
AQ
05/04Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Kura Oncology to Report First Quarter 2022 Financial Results
AQ
04/08Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc..
AQ
04/08Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em..
CI
03/15TRANSCRIPT : Kura Oncology, Inc. Presents at Barclays Global Healthcare Conference 2022, M..
CI
03/08Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Mee..
AQ
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -148 M - -
Net cash 2022 322 M - -
P/E ratio 2022 -5,52x
Yield 2022 -
Capitalization 808 M 808 M -
EV / Sales 2022 -
EV / Sales 2023 29,4x
Nbr of Employees 117
Free-Float 94,2%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 12,12 $
Average target price 35,88 $
Spread / Average Target 196%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President, CEO & Chief Financial Officer
Mollie Leoni Senior Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Faheem Hasnain Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-13.43%808
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546